Phase 2 N=48 Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients
Primary Sjögren's Syndrome
Primary: Change in ESSDAI Total Score — -3.77; -5.54; 11.52; 13.12 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=75 A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
Sjogren's Syndrome
Primary: Percentage of Participants With a Clinically Relevant Decrease in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) Score…
Phase 2 N=28 A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome
Sjogren's Syndrome
Primary: Blood Cell Gene Expression — -0.0291486; 0.1330903; 0.2509076; 0.06726222 log 2 fold change — p=0.0000496
Phase 2 N=32 A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
Primary Sjögren's Syndrome
Primary: Change From Baseline in European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) Score at Day 99 — -2.3; -3.8 Scores on a scale — p=0.262
Phase 2 N=10 A Study of INCB050465 in Primary Sjögren's Syndrome
Primary Sjögren's Syndrome
Primary: Proportion of Participants With a 1 Point or Greater Change on the Salivary Gland Ultrasound (SGUS) Score for Parotid and Submandibular Glands — 0; 0 Participants
Phase 1 N=12 Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome
Primary Sjögren Syndrome
Primary: Change in The European League Against Rheumatism (EULAR) Sjogren's Syndrome Patient Reported Index (ESSPRI) Score From Baseline to Week 24 — -0.125 score on a scale
Phase 3 N=187 A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome
Sjogrens Disease
Primary: Change From Baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) — -3.2; -3.7 Score on a Scale — p=0.4421
N/A N=66 Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome
KERATOCONJUNCTIVITIS SICCA · XEROSTOMIA · SICCA SYNDROME
Primary: The Xerostomia Inventory — 40.2; 39.3 units on a scale — p=0.05
Phase 2 N=69 Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
Primary Sjögren's Syndrome
Primary: Change From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) — 12.0; 11.8; 10.6; 11.0 units on a scale — p=0.397
Phase 2 N=86 Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome
Sjogren's Syndrome
Primary: Number of Participants With Serious Adverse Events (SAE) and Non-serious AEs (Non-SAE) — 0; 3; 2; 4 Participants
Phase 2 N=30 Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome
Primary Sjögren's Syndrome
Primary: Number of Participants With Primary Sjögren's Syndrome With Adverse Events and Death up to Day 85 — 20; 8; 1; 0 count of participants
Phase 2 N=84 Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)
Sjögren's Syndrome · Sjogren's Syndrome
Primary: Change From Baseline to Week 12 in ESSDAI Score — -5.60; -5.29 score on a scale
Phase 2 N=152 Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
Sjogren's Syndrome
Primary: Percentage of Participants Fulfilling Protocol-Specified Response Criteria at Week 12, as Compared to Baseline — 42.9; 43.2; 35.1; 26.5 percentage of participants…
Phase 2 N=24 Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome
Primary Sjögren's Syndrome
Primary: Number of Participants With TEAEs, TESAEs and TEAESIs — 15; 6; 0; 2 Participants
Phase 2 N=104 Exploratory Study for Dry Mouth in Patients With Sjögren's Syndrome
Xerostomia · Sjogren's Syndrome
Primary: Overall Improvement Rate in Dry Mouth Symptoms — 26.0; 20.0; 44.0; 27.1 percentage of participants
Phase 2 N=27 PD of VAY736 in Patients With Primary Sjögren's Syndrome
Primary Sjögren's Syndrome
Primary: Change in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) — 11.1; 14.5; 11.5; 12.5 units on a scale — p=0.678
Phase 2 N=190 Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)
Primary Sjogren Syndrome
Primary: Least Squares Mean Change From Baseline in ESSDAI Score at Week 24 — -6.39; -5.64; -6.93; -8.30 Scores on a scale — p=0.5161
Phase 2 N=183 A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome
Sjögren's Syndrome
Primary: Population 1: Change From Baseline in ESSDAI at Day 169 — -4.1; -6.3 Score on scale
Phase 2 N=34 A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)
Primary Sjögren's Syndrome
Primary: Percentage of Participants Meeting Overall CRESS Response of at Least 3 of 5 Items at Week 24 — 45.5; 11.1 Percentage of participants
Phase 4 N=97 Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention
Sjogren's Syndrome
Primary: Change in Levels of Biomarkers After Dosing With Maxidex — -1.244; -0.29; -0.033; -0.33 ddCt (Delta-Delta-Ct)
N/A N=55 TrueTear in Sjogren's Disease Patients
Dry Eye Syndromes · Sjogren's Syndrome
Primary: Schirmer Testing — 10.2; 0.8; 13.5 mm.
Phase 2 N=273 Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
Sjögren Syndrome
Primary: Cohort 1: Change in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) Score From Baseline at 24 Weeks as Compared to Placebo — -4.0; -7.0; -5.4; -6.9 Unit on a…
N/A N=25 A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS Pts
Autoimmune Diseases
Primary: Standardized Uptake Value (SUV) for 18F-FDG for pSS Participants in Selected Body Areas — 2.9067; 5.0683; 4.0225; 1.4558 Grams per milliliter
Phase 4 N=39 Nasal Spray Study in Sjogren's Dry Eye Disease
Sjogren's Syndrome · Dry Eye
Primary: Mean Change in Cornea Staining — -1.78 units on a scale
Phase 2 N=206 Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
Sjogren's Syndrome
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 0; 0; 127; 43 Participants
N/A N=286 Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis
Dry Eye Syndromes · Rheumatoid Arthritis
Primary: Number of Participants Diagnosed With Rheumatoid Arthritis Also Found to Have Dry Eye Disease — 275 participants
Phase 2 N=116 Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients
Corneal Erosion
Primary: Change From Baseline to Week 12 in Total Corneal Fluorescein Staining — -2.55; -0.37 units on a scale
Phase 2 N=142 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24
Phase 3 N=11 RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)
Sjogren-Larsson Syndrome
Primary: Visual Index Ichthyosis Severity (VIIS) Scaling Score as Assessed by the Investigator in ADX-102 Treated Patients — -0.7 units on a scale
N/A N=100 Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms
Xerostomia
Primary: Mean Response to the Question 1 'Relieving the Discomfort of Dry Mouth' in Product Performance and Attributes Questionnaire 3 (PPAQ3) at 120 Minutes(Mins) Post Treatment…